Presentations

Biomarker testing patterns and patient outcomes for metastatic NSCLC, CRC, and metastatic/recurrent HNSCC at Texas Oncology.

May 20, 2026

2026 ASCO Annual Meeting

Read More 9

Front-line treatment approaches in multiple myeloma: real-world data from a community-based oncology network

Apr 21, 2026

Front. Oncol., 21 April 2026 Sec. Hematologic Malignancies

Read More 9

Management of CML in community setting: Basis for a quality initiative

Oct 7, 2025

2025 ASCO Quality Care Symposium

Read More 9

Real-world Outcomes Among Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Initiating Teclistamab (Tec) at a Large Community Oncology Center in the US

Sep 20, 2025

2025 International Myeloma Society Annual Meeting - Toronto, Canada | Virtual

Read More 9

Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer.

May 31, 2025

ASCO Annual Meeting, 2025

Read More 9

Biomarker testing patterns among patients newly diagnosed with prostate cancer in a community oncology network

Feb 13, 2025

ASCO Genitourinary Cancers Symposium 2025, Prostate Biomarkers Poster Session

Read More 9

Biomarker testing patterns among patients newly diagnosed with non-small cell lung, prostate, and bladder cancer

Jan 22, 2025

Genetics in Medicine Open 3: Volume 3, Supplement 2

Read More 9

Increased Incidence of Non-Hematologic Malignancy in Patients with Monoclonal Gammopathy of Undertermined Significance

Nov 5, 2024

Blood (2024) 144 (Supplement 1): 6884.

Read More 9

Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers

Nov 5, 2024

Blood (2024) 144 (Supplement 1): 7851.

Read More 9

Oncology care model cost data for breast, lung, and multiple myeloma: Influence of outpatient rehabilitation therapy services

Sep 30, 2024

JCO Oncol Pract 20, 14(2024) Volume 20, Number 10_suppl

Read More 9

A Unique Model: Partnership between Community Oncology and Pharma

Jun 1, 2024

ASCO Quality 2024, Poster Session

Read More 9

The association of timely comprehensive genomic profiling with precision oncology treatment use and patient outcomes in advanced non-small cell lung cancer

Mar 7, 2024

JCO Precision Oncology, Volume 8 • 2024

Read More 9

Evaluation of the impact of a decision-support platform (Trapelo) on testing patterns for patients with advanced solid tumors 

Oct 28, 2023

ASCO Quality 2023, Poster Session B

Read More 9

Innovative biomarker testing initiative in a community oncology setting 

Oct 27, 2023

ASCO Quality 2023, Poster Session A

Read More 9

PP01. 63 Real-World Assessment of Clinical Outcomes Associated with Immunotherapy (IO) and chemotherapy in Non–Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases and METexon14 Skipping Mutations Treated in US Community Centers

Mar 23, 2023

Journal of Thoracic Oncology | Volume 18 Issue 3 Supplement, e1-e50

Read More 9

A real-world assessment of PIK3CA testing and Alpelisib treatment patterns among metastatic breast cancer patients in a community oncology setting

Dec 11, 2021

San Antonio Breast Cancer Symposium

Read More 9